Introduction {#s1}
============

Marginal zone lymphoma (MZL) is an indolent B-cell lymphoma that accounts for about 5-17% of all non-Hodgkin's lymphomas (NHLs) in adults \[[@R01]\]. MZL arises from post-germinal center marginal zone B cells present in lymph nodes and extranodal tissues. The neoplastic cells share a similar immunophenotype: positive for B-cell markers CD19, CD20, and CD22, and negative for CD5, CD10, and usually CD23 \[[@R02]\]. According to the REAL/WHO classification systems, MZL comprises three subtypes: extranodal marginal zone B-cell lymphoma, also called mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma (NMZL) and splenic marginal zone B-cell lymphoma (SMZL) (± villous lymphocytes). MALT lymphomas are the most common type of MZL, which constitute about 5% of all NHLs \[[@R05]\]. MALT lymphomas are divided into gastric and non-gastric MALT lymphomas based on the localization at initial diagnosis. The most common manifestation sites of non-gastric MALT lymphomas are the salivary glands, the thyroid, the upper airways, the lung, the ocular adnexa, the breast, the liver, the urothelial system, the skin, the dura and other soft tissues \[[@R01]\]. In the head and neck region except for the salivary glands, the development of this neoplasm is very rare \[[@R06]\]. Thus far, only few previous cases of MALT lymphoma with involvement of hard palate have been reported \[[@R06]\]. Herein, we report on a case of MALT lymphoma of the parotid gland with concomitant involvement of an extremely rare site of occurrence: the hard palate.

Case Report {#s2}
===========

A 61-year-old woman was admitted to the Department of Otolaryngology with a 1-year history of swelling in the right palatal region and problems with pronunciation and chewing. Also, she suffered from a painless, progressively enlarging mass in the right preauricular region. On physical examination, swelling of the right parotid gland ([Fig. 1a](#F1){ref-type="fig"}) and a 2 × 2.5 cm mass with central ulceration on the right hard palate ([Fig. 1b](#F1){ref-type="fig"}) were noted. She had no history of fever, weight loss or night sweats. No lymph nodes were palpated in the head and neck region. Blood count was as follows: hemoglobin 13 g/dL, total leukocyte count 6,240/mm^3^ (neutrophil 54%, lymphocyte 36%) and platelet 185,000/mm^3^. Biochemical tests showed normal lactate dehydrogenase (LDH), beta-2 microglobulin levels and protein electrophoresis were normal. Cervical magnetic resonance imaging (MRI) confirmed a 2 × 2.5 cm mass on the right side of the hard palate and a 2.5 × 3.5 cm mass in the right parotid gland region ([Fig. 2a, b and c](#F2){ref-type="fig"}). Incisional biopsy of the palatal mass revealed subepithelial infiltration of atypical centrocyte-like cells with or without clear cytoplasm that stained for CD20 and kappa light chain, and did not stain for CD5, CD10, CD23 and lambda light chain, suggesting marginal zone B-cell lineage ([Fig. 3a, b](#F3){ref-type="fig"}). Further examination included hepatitis B, C, HIV testing, chest and abdominopelvic computed tomography (CT), bone marrow aspirate and biopsy, and gastroscopy with multiple biopsies, all of which revealed unremarkable findings. The final diagnosis was MALT lymphoma with involvement of two extralymphatic sites: parotid gland and hard palate. Screening for autoimmune disorders including Sjogren's syndrome was negative. Because of multiple extranodal involvements, a multi-agent chemotherapy regimen, rituximab, cyclophosphamide, doxorubicin, vincristine, and methylprednisolone (R-CHOP) was started. After five cycles, the patient had improved quality of life through the recovery of orofacial functions such as pronunciation and chewing. After six cycles, mass arising from the right side of the hard palate almost totally disappeared and the ulceration totally regressed ([Fig. 4a](#F4){ref-type="fig"}). Also, swelling on the right parotid gland significantly regressed. MRI confirmed the disappereance of the mass in the right palatal region ([Fig. 4b](#F4){ref-type="fig"}) and the marked regression of the enlargement of the right parotid gland. Chemotherapy was completed up to eight cycles. She has been in complete remission (CR) without any evidence of recurrent lymphoma infiltration for the past 44 months.

![Clinical features of the patient at admission. (a) Swelling of the right parotid gland. (b) A 2 × 2.5 cm mass with central ulceration on the right hard palate.](jocmr-08-824-g001){#F1}

![Findings on cervical MRI. (a) Isointense mass lesion on the hard palate on sagittal, T1-weighted plane. (b) Mass lesion on the right side of the hard palate on coronal, T1-weighted, fat-saturated, contrast-enhanced sequence. (c) Mass lesion in the right parotid gland on axial, T1-weighted, contrast-enhanced plane.](jocmr-08-824-g002){#F2}

![Histopathological findings of the palatal mass. (a) Subepithelial infiltration of atypical centrocyte-like cells with or without clear cytoplasm (H&E stain, × 400). (b) Infiltrated cells in the hard palate with CD20 expression (H&E stain, × 400).](jocmr-08-824-g003){#F3}

![Case image and clinical findings after six cycles of chemotherapy. (a) Total regression of the ulcerated mass on the right hard palate. (b) Disappearance of the mass at the right palatal region on T1-weighted coronal MRI.](jocmr-08-824-g004){#F4}

Discussion {#s3}
==========

MZL is a rare type of NHL characterized by indolent nature with three subgroups: MALT lymphoma, NMZL and SMZL. A variety of factors including chronic infections (e.g. *Helicobacter pylori*, HCV, *Campylobacter jejuni, Borrelia burgdorferi*, and *Chlamydia psittaci*) and autoimmune diseases (e.g. rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematosus and Wegener's granulomatosis) have been reported to be associated with MZL \[[@R01]\]. MALT lymphomas are the most common subgroup of MZL and also account for a significant proportion of extranodal lymphomas \[[@R05], [@R06]\]. Isaacson and Wright in 1983 first described MALT lymphoma as a low grade B-cell lymphoma \[[@R15]\]. For MALT lymphomas, average age at diagnosis is 60 years with a slight female predominance \[[@R16]\]. MALT lymphomas occur most commonly in stomach and they can be found virtually in every organ including the intestine, salivary glands, thyroid, lung and orbit, and also though less frequently, the skin, urinary bladder and the gonads \[[@R17]\].

NHLs of the salivary gland account for only 1.7% of salivary gland malignancies \[[@R18]\]. Salivary gland NHL comprises 4% of all NHLs and 4.7% of extranodal NHLs \[[@R19], [@R20]\]. The most frequently involved gland is the parotid gland, followed by submandibular gland, minor salivary glands and sublingual glands \[[@R18], [@R19], [@R21]\]. MALT lymphoma is the most common type of NHL of the salivary gland \[[@R09], [@R23]\]. It was reported that MALT lymphoma very rarely develops in the head and neck region except for the salivary glands \[[@R06]\]. For MALT lymphomas, the second most common site of involvement following the stomach is the salivary gland \[[@R24]\]. In the present case, one of the involved extranodal sites is the parotid gland, an acknowledged location of MALT lymphoma.

Etiopathogenesis of MALT lymphomas is not fully understood. MALT lymphomas are usually associated with chronic antigenic stimulation triggered by persistent infections and/or autoimmune processes \[[@R01]\]. Wotherspoon et al suggested that *Helicobacter pylori*-associated chronic gastric inflammation may induce gastric MALT lymphoma \[[@R25]\]. Kahl and Yang reported that *H. pylori* infection is present in 90% of gastric MALT lymphoma cases \[[@R26]\]. There are also several reports implicating infectious agents and autoimmune diseases in the pathogenesis of certain nongastric MALT lymphomas \[[@R01], [@R27]\]. Most salivary gland MALT lymphomas are thought to develop on the basis of chronic antigenic stimulation in the presence of Sjogren's syndrome \[[@R28]\]. Our patient had parotid gland involvement, but showed no sign of autoimmune disease neither at diagnosis nor during the disease course.

Primary lymphomas of the oral cavity are rare \[[@R34]\]. In approximately 2% of all extranodal lymphomas, the primary site of involvement is the oral cavity including the palate, gingiva, tongue, buccal mucosa, lips, and floor of the mouth \[[@R35]\]. Primary lymphomas of the oral cavity in non-immuncompromised patients most commonly present as diffuse large B-cell lymphoma (DLBL). Mantle cell lymphoma, MALT lymphoma, Burkitt's lymphoma, lymphomablastic lymphoma, peripheral T-cell lymphoma and anaplastic large cell lymphoma have been reported as well \[[@R36]\]. Kemp et al evaluated 40 cases of oral cavity NHLs \[[@R37]\]. Most cases were of B-cell lineage (98%), the majority of which (58%) were histologically subtyped as DLBL, followed by follicular lymphoma (15%), MALT lymphoma (13%), plasma cell tumors (8%) and small lymphocytic lymphoma/chronic lymphocytic leukemia (5%) \[[@R37]\]. Sites of involvement included the upper jaw (maxilla or palatal bone) (28%), mandible (20%), palatal soft tissue (20%), vestibule and gingiva (17%), buccal mucosa (9%), floor of mouth (3%) and the lower lip (3%) \[[@R37]\]. The hard palate is an uncommon site of MALT lymphoma and to our knowledge, there are only several case reports of a similar case \[[@R06]\]. Tauber et al reported the first case of MALT lymphoma of the hard palate \[[@R06]\]. Clinical details of the patients diagnosed with MALT lymphoma of the hard palate in the literature including our case are summarized in [Table 1](#T1){ref-type="table"} \[[@R06]\]. The described cases show a strong female predominance (9:1) and are mostly of older age. Four to seven percent of patients with Sjogren's syndrome develop malignant B-cell lymphomas, 48-75% of which are MALT lymphomas \[[@R38], [@R39]\]. Sjogren's syndrome plays a major role in the development of MALT lymphoma of the oral and maxillofacial region, most frequently being located in the parotid gland \[[@R40]\]. As depicted in [Table 1](#T1){ref-type="table"}, Sjogren's syndrome was observed in one-third of MALT lymphoma patients with palatal involvement. Considering the importance of Sjogren's syndrome, we screened and ruled out autoimmune disorders in our patient. The most frequent clinical appearance of palatal MALT lymphomas is non-tender yet rarely ulcerated mass \[[@R08]\]. To our knowledge, only two previous reports described ulcerated masses associated with palatal MALT lymphomas \[[@R01], [@R07]\]. Our patient also presented with ulceration located at the center of the hard palate. She had multiple extranodal involvements, hard palate and parotid gland, as reported in the two other cases \[[@R04], [@R06]\]. Our patient had no underlying autoimmune disease in contrast to the two aferomentioned cases \[[@R04], [@R06]\]. MALT lymphoma in general is an indolent disease, with a 5-year overall survival rate of 86-95%. Patients with localized and disseminated disease show no significant difference in clinical course \[[@R24], [@R43]\]. The follow-up durations of MALT lymphoma patients with hard palate involvement were between 6 and 48 months; our case has the second longest follow-up duration ([Table 1](#T1){ref-type="table"}) \[[@R06]\]. One of the patients was lost to follow-up and one had succembed to the disease due to relapse. There is no optimal treatment for MALT lymphomas because of their relative infrequency and heterogeneity in disease biology, clinical presentation and behavior. In non-gastric MALT lymphomas with symptomatic local disease, local treatment (surgery or radiotherapy) results in excellent disease control \[[@R44]\]. For symptomatic disseminated disease, chemotherapy has commonly been used, with 75% CR rate and 5-year event-free survival and overall survival rates of 50% and 75%, respectively \[[@R24], [@R43], [@R45]\]. More recently, anti-CD20 monoclonal antibody rituximab, which alone or in combination with chemotherapy demonstrated efficacy against B-cell lymphomas, has also been used effectively in MALT lymphomas \[[@R48]\]. Given the risk of occult disseminated disease, extensive workup procedures are needed in non-gastric MALT lymphomas including a staging system based on the Ann Arbor classification and the modification for primary gastric lymphoma by Musshoff \[[@R53], [@R54]\]. According to the aforementioned classification systems, patients were divided to three subgroups: localized disease, locally disseminated disease and disseminated disease. Since our patient had disseminated disease with involvement of multiple extranodal sites (hard palate and parotid gland), we administered rituximab-based chemotherapy. Of the other two reported disseminated MALT lymphomas with hard palate involvement, one was treated with chemotherapy and radiotherapy and the other with rituximab ([Table 1](#T1){ref-type="table"}). All patients with localized disease except one were treated with surgical excision of the mass on the hard palate while the single patient experienced spontaneous regression of the tumor ([Table 1](#T1){ref-type="table"}). Cases of spontaneous regression of several MALT lymphoma of the rectum and ocular adnexa have been reported \[[@R55], [@R56]\]. Of the described palatal MALT lymphomas, one showed CR after the biopsy ([Table 1](#T1){ref-type="table"}) \[[@R12]\]. The mechanisms for spontaneous regression of tumors can be explained by several factors: immune mediation, tumor inhibition by growth factors and/or cytokines, induction of differentiation, elimination of carcinogens, tumor necrosis or angiogenesis inhibition, psychological factors, apoptosis and epigenetic mechanisms \[[@R57], [@R58]\]. In the above-mentioned case, Sakuma et al speculated that traumatic effect and localized infection induced by the surgical intervention might have activated tumor immunity and hence provided spontaneous regression \[[@R12]\].

###### Clinical Features of MALT Lymphoma With Hard Palate Involvement

  Case   Ref.                            Age/sex   Autoimmune disease                  Size (mm)   Location                                            Palatal ulceration   Treatment               Response    Outcome   FU
  ------ ------------------------------- --------- ----------------------------------- ----------- --------------------------------------------------- -------------------- ----------------------- ----------- --------- -----------
  1      Tauber et al \[[@R06]\]         71/F      NR                                  20          Hard + soft palate                                  Yes                  Excision                CR          A         4 years
  2      Ayers et al \[[@R07]\]          64/F      NR                                  NR          Hard palate                                         No                   \-                      \-          \-        LTF
  3      Manveen et al \[[@R08]\]        40/M      No                                  45          Hard palate                                         No                   Excision                CR          A         6 months
  4      Dunn et al \[[@R09]\]           64/F      SS, scleroderma, cryoglobulinemia   20          Hard palate + parotid + nasopharynx + cervical LN   NR                   Chemo + RT              Fourth CR   A         57 months
  5      Kolokotronis et al \[[@R10]\]   73/F      No                                  NR          Hard palate                                         NR                   Excision                RD          DOD       15 months
  6      Pijpe et al \[[@R11]\]          42/F      SS                                  20          Hard palate + parotid                               NR                   Chemo (R)               CR          A         6 months
  7      Sakuma et al \[[@R12]\]         70/F      SS                                  17          Hard palate                                         Yes                  Spontanous regression   CR          A         38 months
  8      Shah et al \[[@R13]\]           55/F      NR                                  19          Hard + soft palate                                  No                   Excision                CR          A         2 years
  9      Abe et al \[[@R14]\]            64/F      No                                  30          Hard palate                                         No                   Excision                \-          \-        \-
  10     Present case                    61/F      No                                  25          Hard palate + parotid                               Yes                  Chemo (R-CHOP)          CR          A         44 months

A: alive; CR: complete remission; DOD: died of disease; FU: follow-up; NR: not recorded; RD: relapsed disease; R: rituximab; Ref.: references; RT: radiation therapy; SS: Sjogren's syndrome; LTF: lost to follow-up.

In conclusion, based on information synthesized from the literature review, extensive workup procedures, including history and physical examination, complete blood cell counts and basic biochemical studies including tests of renal and liver function, LDH and β2-microglobulin levels, protein electrophoresis; HIV, HCV, and HBV serologies; CT scans of the cervical region, chest, abdomen, and pelvis; bone marrow aspirate and biopsy; and gastroduodenal endoscopy with multiple biopsies to exclude a concomitant gastric involvement are mandatory in all MALT lymphomas because of the risk of occult disseminated disease. Current management guidelines recommend a "patient-tailored" approach taking into account the stage, site and clinical characteristics of the individual non-gastric MALT lymphoma patient. Therapeutic strategies for MALT lymphomas are not standardized due to the small number of cases described in the head and neck region. Herein, we described a rare MALT lymphoma patient of the hard palate with concomitant parotid gland involvement, who remained disease free for 44 months. In case of multiorgan involvement, systemic therapy with either chemotherapy or chemotherapy in combination with rituximab seems to be an appropriate option for MALT lymphoma of the head and neck region.
